Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business ...

A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against ...

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its ...

COPENHAGEN (Reuters) -Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug ...

Today's biotech news updates include rogue CAR-T treatment in Spain, halting illegal Wegovy sales, and Pfizer fumbling the bag.

First, Novo Nordisk, the company behind Ozempic and Wegovy, outgrew its native Denmark. Now, it’s bigger than Tesla. Shares in the pharmaceutical giant rose jumped more than 8% Thursday, pushing ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...